## C4 Therapeutics Secures New Roche Deal for Degrader-Antibody Conjugate Platform
C4 Therapeutics has inked a new strategic collaboration and license agreement with pharmaceutical giant Roche, focusing on the development of degrader-antibody conjugates (DACs). This deal signals continued validation for C4T's targeted protein degradation platform and deepens its existing partnership with one of the world's largest drugmakers. The agreement centers on a novel therapeutic approach that combines antibody-drug conjugate (ADC) technology with C4T's proprietary TORPEDO® platform to create degraders that can be delivered with precision to specific cells.

The financial terms include an upfront payment of $70 million to C4 Therapeutics, with the potential for future milestone payments exceeding $600 million, plus tiered royalties on net sales of any resulting products. C4T will lead discovery and early research activities, while Roche will assume responsibility for subsequent development, manufacturing, and commercialization. This structure allows C4T to leverage Roche's global infrastructure and commercial reach while retaining upstream research control and significant economic upside.

The partnership intensifies competition in the burgeoning targeted protein degradation field and places C4T in a strengthened strategic position. The deal provides non-dilutive capital to advance C4T's internal pipeline and validates the DAC modality as a next-generation approach in oncology and beyond. It also increases pressure on other biotechs in the space to secure similar partnerships with major pharma to fund costly development and navigate complex commercialization pathways.
---
- **Source**: Seeking Alpha
- **Sector**: The Lab
- **Tags**: biotech, pharma, collaboration, oncology, protein degradation
- **Credibility**: unverified
- **Published**: 2026-04-09 22:39:31
- **ID**: 57665
- **URL**: https://whisperx.ai/en/intel/57665